{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:30:20Z","timestamp":1790314220172,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T00:00:00Z","timestamp":1542672000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s11523-018-0606-x","type":"journal-article","created":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T23:27:57Z","timestamp":1542670077000},"page":"801-808","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Olaparib Tablet: A Review in Ovarian Cancer Maintenance Therapy"],"prefix":"10.1007","volume":"13","author":[{"given":"Young-A","family":"Heo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohita","family":"Dhillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,20]]},"reference":[{"key":"606_CR1","doi-asserted-by":"publisher","unstructured":"Labidi-Galy SI, Papp E, Hallberg D, et al. High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun. 2017. https:\/\/doi.org\/10.1038\/s41467-017-00962-1 .","DOI":"10.1038\/s41467-017-00962-1"},{"key":"606_CR2","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.2147\/DDDT.S151420","volume":"11","author":"C Audibert","year":"2017","unstructured":"Audibert C, Perlaky A, Stuntz M, et al. Variability in the therapeutic management of advanced ovarian cancer patients: a five-country survey of oncologists. Drug Des Devel Ther. 2017;11:3471\u20139.","journal-title":"Drug Des Devel Ther"},{"issue":"Suppl 2","key":"606_CR3","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.1016\/j.ijgo.2015.06.007","volume":"131","author":"JS Berek","year":"2015","unstructured":"Berek JS, Crum C, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2015;131(Suppl 2):S111\u201322.","journal-title":"Int J Gynaecol Obstet"},{"key":"606_CR4","unstructured":"National Comprehensive Cancer Network. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer (NCCN clinical practice guidelines in oncology). 2018. http:\/\/www.nccn.org\/ . Accessed 3 Jul 2018."},{"key":"606_CR5","doi-asserted-by":"publisher","unstructured":"Suh DH, Kim M, Lee KH, et al. Major clinical research advances in gynecologic cancer in 2017. J Gynecol Oncol. 2018. https:\/\/doi.org\/10.3802\/jgo.2018.29.e31 .","DOI":"10.3802\/jgo.2018.29.e31"},{"issue":"1","key":"606_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s13669-018-0233-7","volume":"7","author":"CC Gunderson","year":"2018","unstructured":"Gunderson CC, Erickson BK, Buechel ME, et al. The current landscape of PARP inhibitors in ovarian cancer. Curr Obstet Gynecol Rep. 2018;7(1):20\u20137.","journal-title":"Curr Obstet Gynecol Rep"},{"key":"606_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejca.2016.03.005","volume":"60","author":"JA Ledermann","year":"2016","unstructured":"Ledermann JA, Drew Y, Kristeleit RS. Homologous recombination deficiency and ovarian cancer. Eur J Cancer. 2016;60:49\u201358.","journal-title":"Eur J Cancer"},{"issue":"2","key":"606_CR8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s40259-015-0125-6","volume":"29","author":"JE Frampton","year":"2015","unstructured":"Frampton JE. Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer. BioDrugs. 2015;29(2):143\u201350.","journal-title":"BioDrugs"},{"issue":"3","key":"606_CR9","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s11523-016-0435-8","volume":"11","author":"J Mateo","year":"2016","unstructured":"Mateo J, Moreno V, Gupta A, et al. An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib. Target Oncol. 2016;11(3):401\u201315.","journal-title":"Target Oncol"},{"key":"606_CR10","unstructured":"AstraZeneca. Lynparza\u00ae (olaparib) tablets: US prescribing information. 2018. http:\/\/www.fda.gov . Accessed 9 Aug 2018."},{"key":"606_CR11","unstructured":"European Medicines Agency. Lynparza (olaparib): hard capsules (50 mg), and film-coated tablets (100 mg and 150 mg): summary of product characteristics 2018. http:\/\/www.ema.europa.eu \/. Accessed 9 Aug 2018."},{"key":"606_CR12","unstructured":"AstraZeneca. Lynparza receives approval in Japan for the treatment of advanced ovarian cancer [media release]. 19 January 2018."},{"key":"606_CR13","unstructured":"AstraZeneca. Q1 2018 results [media release]. 18 May 2018."},{"issue":"20","key":"606_CR14","doi-asserted-by":"publisher","first-page":"6581","DOI":"10.1021\/jm8001263","volume":"51","author":"KA Menear","year":"2008","unstructured":"Menear KA, Adcock C, Boulter R, et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin- 1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem. 2008;51(20):6581\u201391.","journal-title":"J Med Chem"},{"issue":"21","key":"606_CR15","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72(21):5588\u201399.","journal-title":"Cancer Res"},{"key":"606_CR16","doi-asserted-by":"crossref","unstructured":"Bizzaro F, Marchetti AC, Decio A, et al. Patient derived ovarian cancer xenograft (OC-PDX) to study the response of the PARP inhibitor olaparib [abstract no. 2816]. Cancer Res. 2018;78(13 Suppl).","DOI":"10.1158\/1538-7445.AM2018-2816"},{"issue":"4","key":"606_CR17","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00280-016-3124-5","volume":"78","author":"H Swaisland","year":"2016","unstructured":"Swaisland H, Plummer R, So K, et al. Olaparib does not cause clinically relevant QT\/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies. Cancer Chemother Pharmacol. 2016;78(4):775\u201384.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"606_CR18","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00280-015-2836-2","volume":"76","author":"R Plummer","year":"2015","unstructured":"Plummer R, Swaisland H, Leunen K, et al. Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours. Cancer Chemother Pharmacol. 2015;76(4):723\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"606_CR19","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1016\/j.clinthera.2016.08.010","volume":"38","author":"L Dirix","year":"2016","unstructured":"Dirix L, Swaisland H, Verheul HMW, et al. Effect of itraconazole and rifampin on the pharmacokinetics of olaparib in patients with advanced solid tumors: results of two phase I open-label studies. Clin Ther. 2016;38(10):2286\u201399.","journal-title":"Clin Ther"},{"issue":"10","key":"606_CR20","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1080\/00498254.2016.1241449","volume":"47","author":"A McCormick","year":"2017","unstructured":"McCormick A, Swaisland H. In vitro assessment of the roles of drug transporters in the disposition and drug-drug interaction potential of olaparib. Xenobiotica. 2017;47(10):903\u201315.","journal-title":"Xenobiotica"},{"issue":"6","key":"606_CR21","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/00498254.2017.1346332","volume":"48","author":"A McCormick","year":"2018","unstructured":"McCormick A, Swaisland H, Reddy VP, et al. In vitro evaluation of the inhibition and induction potential of olaparib, a potent poly(ADP-ribose) polymerase inhibitor, on cytochrome P450. Xenobiotica. 2018;48(6):555\u201364.","journal-title":"Xenobiotica"},{"issue":"9","key":"606_CR22","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274\u201384.","journal-title":"Lancet Oncol"},{"issue":"15","key":"606_CR23","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","volume":"366","author":"J Ledermann","year":"2012","unstructured":"Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382\u201392.","journal-title":"N Engl J Med"},{"issue":"Suppl 5","key":"606_CR24","doi-asserted-by":"crossref","first-page":"v344","DOI":"10.1093\/annonc\/mdx372.036","volume":"28","author":"AM Oza","year":"2017","unstructured":"Oza AM, Combe P, Ledermann J, et al. Evaluation of tumour responses and olaparib efficacy in platinumsensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21) [abstract no. 965P]. Ann Oncol. 2017;28(Suppl 5):v344.","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"606_CR25","doi-asserted-by":"crossref","first-page":"v331","DOI":"10.1093\/annonc\/mdx372.002","volume":"28","author":"R Penson","year":"2017","unstructured":"Penson R, Kaminsky-Forrett MC, Ledermann J, et al. Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: phase III SOLO2 trial (ENGOT Ov-21) [abstract no. 932PD]. Ann Oncol. 2017;28(Suppl 5):v331.","journal-title":"Ann Oncol"},{"issue":"8","key":"606_CR26","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S1470-2045(18)30343-7","volume":"19","author":"M Friedlander","year":"2018","unstructured":"Friedlander M, Gebski V, Gibbs E, et al. Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncol. 2018;19(8):1126\u201334.","journal-title":"Lancet Oncol"},{"issue":"8","key":"606_CR27","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","volume":"15","author":"J Ledermann","year":"2014","unstructured":"Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852\u201361.","journal-title":"Lancet Oncol"},{"issue":"11","key":"606_CR28","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(16)30376-X","volume":"17","author":"JA Ledermann","year":"2016","unstructured":"Ledermann JA, Harter P, Gourley C, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016;17(11):1579\u201389.","journal-title":"Lancet Oncol."},{"key":"606_CR29","doi-asserted-by":"publisher","unstructured":"Friedlander M, Matulonis U, Gourley C, et al. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br J Cancer. 2018. https:\/\/doi.org\/10.1038\/s41416-018-0271-y .","DOI":"10.1038\/s41416-018-0271-y"},{"issue":"11","key":"606_CR30","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/bjc.2016.348","volume":"115","author":"JA Ledermann","year":"2016","unstructured":"Ledermann JA, Harter P, Gourley C, et al. Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. Br J Cancer. 2016;115(11):1313\u201320.","journal-title":"Br J Cancer"},{"key":"606_CR31","unstructured":"European Medicines Agency. Lynparza: CHMP assessment report on extension of marketing authorisation grouped with a variation 2018. http:\/\/www.ema.europa.eu \/. Accessed 9 Aug 2018."},{"key":"606_CR32","doi-asserted-by":"crossref","unstructured":"Korach J, Freyer G, Banerjee S, et al. Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): phase III SOLO2 trial [abstract no. 952P]. Ann Oncol. 2018;29(Suppl 8).","DOI":"10.1093\/annonc\/mdy285.160"},{"issue":"Suppl 5","key":"606_CR33","doi-asserted-by":"publisher","first-page":"v145","DOI":"10.1093\/annonc\/mdw360","volume":"27","author":"JA Ledermann","year":"2016","unstructured":"Ledermann JA, Sessa C, Colombo N, on behalf of the ESMO guidelines committee. eUpdate \u2013 ovarian cancer treatment recommendations. Ann Oncol. 2016;27(Suppl 5):v145.","journal-title":"Ann Oncol"},{"issue":"Suppl 6","key":"606_CR34","doi-asserted-by":"publisher","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","volume":"24","author":"JA Ledermann","year":"2013","unstructured":"Ledermann JA, Raja FA, Fotopoulou C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi24\u201332.","journal-title":"Ann Oncol"},{"issue":"9","key":"606_CR35","doi-asserted-by":"publisher","first-page":"A412","DOI":"10.1016\/j.jval.2017.08.088","volume":"20","author":"R Hettle","year":"2017","unstructured":"Hettle R, Sackeyfio A, Gill J, et al. Comparative efficacy and safety of olaparib 300 mg tablets bid and niraparib 300 mg tablets qd as maintenance treatment after response to chemotherapy in patients with platinum-sensitive relapsed germline BRCA-mutated ovarian cancer (PSROC) [abstract no. PCN6]. Value Health. 2017;20(9):A412.","journal-title":"Value Health"},{"issue":"Suppl 1","key":"606_CR36","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ygyno.2018.04.094","volume":"149","author":"A Sackeyfio","year":"2018","unstructured":"Sackeyfio A, Nussey F, Friedlander M, et al. Comparative efficacy and tolerability of the PARP inhibitors, olaparib 300 mg tablets bid, niraparib 300 mg capsules qd and rucaparib 600 mg tablets bid as maintenance treatment in BRCA-mutated (BRCAm) platinum-sensitive relapsed ovarian [abstract no. 83]. Gynecol Oncol. 2018;149(Suppl 1):43\u20134.","journal-title":"Gynecol Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-018-0606-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-018-0606-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-018-0606-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,15]],"date-time":"2020-11-15T15:10:57Z","timestamp":1605453057000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-018-0606-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,20]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["606"],"URL":"https:\/\/doi.org\/10.1007\/s11523-018-0606-x","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,20]]},"assertion":[{"value":"20 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Young-A Heo and Sohita Dhillon are salaried employees of Adis\/Springer, are responsible for the article content and declare no relevant conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}